GSK Investigational Site

Móstoles/Madrid 28935

0 studies enrolling now · 10 studies all time

What they study most

AIDS, Atherosclerosis, HIV Infections, Infection, Human Immunodeficiency Virus, Infection, Human Immunodeficiency Virus I, Infections, Papillomavirus, Influenza, Human, Neoplasms, Breast

Studies at this site

• A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) — Completed
• A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults — Completed
• Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects — Completed
• A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily — Completed
• Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons — Completed
• A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial) — Completed
• Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine — Completed
• Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital — Completed
• SB-480848 In Subjects With Coronary Heart Disease — Completed
• Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer — Completed